# Eimeria maxima: Midgut [Coccidiosis in Chickens](/knowledge/parasites/avian-parasites/causes-coccidiosis-chickens-etiology-transmission-predisposing-factors), Lesion Scoring and Immunity
## Key Takeaways
- *Eimeria maxima* is a significant avian pathogen causing midgut coccidiosis in chickens, characterized by villous atrophy, crypt hyperplasia, and a characteristic orange-pink mucoid exudate in the jejunum and proximal ileum.
- A standardized lesion scoring system (0-4) is crucial for assessing *E. maxima* severity, evaluating anticoccidial efficacy, and monitoring vaccine challenge studies, with peak lesion development occurring 5-6 days post-infection.
- Definitive diagnosis involves fecal flotation for large, ellipsoidal oocysts, histopathology showing developmental stages within enterocytes, and potentially molecular methods like PCR for species identification.
- Protective immunity against *E. maxima* is primarily cell-mediated, involving CD4+ and CD8+ T cells and interferon-gamma production, making it a key component in live coccidiosis vaccines due to its strong immunogenicity.
- Control strategies integrate management practices (litter dryness, ventilation), anticoccidial drugs (with documented resistance issues), and live vaccination, necessitating rotation or shuttle programs to maintain efficacy.
- Differential diagnosis for *E. maxima* lesions includes necrotic enteritis (*Clostridium perfringens*), other *Eimeria* species (*E. acervulina*, *E. necatrix*), salmonellosis, and viral infections like avian influenza and Newcastle disease.
---
## Introduction
Coccidiosis remains one of the most economically significant parasitic diseases of commercial poultry worldwide. Among the seven recognized species of *Eimeria* that infect chickens (*Gallus gallus domesticus*), *Eimeria maxima* occupies a distinct niche as the primary pathogen of the midgut (jejunum and proximal ileum). This apicomplexan protozoan is characterized by its moderate to high pathogenicity, pronounced immunogenicity, and the production of large, ellipsoidal oocysts that are readily identifiable on fecal flotation. The clinical and subclinical impacts of *E. maxima* infection include reduced weight gain, impaired feed conversion efficiency, and increased flock heterogeneity, all of which contribute to substantial economic losses in broiler and layer operations [1, 2].
This article provides a detailed examination of *E. maxima* biology, the standardized lesion scoring system used for midgut coccidiosis, and the immunological mechanisms that govern protective immunity. The discussion is framed within the context of differential diagnosis from other enteric pathogens, including bacterial agents such as *Clostridium perfringens* (the cause of [necrotic enteritis](/knowledge/bacteria/avian-bacteria/necrotic-enteritis-poultry)) and other *Eimeria* species that occupy adjacent intestinal segments [3, 4].
## Etiology and Life Cycle
*Eimeria maxima* is an obligate intracellular parasite belonging to the phylum Apicomplexa, family Eimeriidae. The parasite exhibits a high degree of host specificity, infecting only chickens, and demonstrates strict site specificity for the midgut epithelium [1]. The life cycle is monoxenous (completed within a single host) and follows the typical coccidian pattern of asexual multiplication (schizogony or merogony) followed by sexual reproduction (gametogony) and oocyst formation.
The life cycle begins when a susceptible chicken ingests sporulated oocysts from contaminated litter, feed, or water. Each sporulated oocyst contains four sporocysts, each harboring two sporozoites. Following ingestion, mechanical disruption of the oocyst wall in the gizzard releases sporocysts, and bile salts and pancreatic enzymes in the small intestine trigger the release of sporozoites [2]. Sporozoites penetrate the intestinal epithelium and migrate to the crypt epithelium of the jejunum, where they initiate the first asexual generation.
The prepatent period for *E. maxima* is approximately 121 to 123 hours (5 days), which is longer than that of *E. acervulina* (4 days) but shorter than that of *E. tenella* (6 days) [3]. The patent period, during which oocysts are shed in the feces, typically lasts 4 to 8 days. Each oocyst can produce hundreds of thousands of progeny, leading to rapid amplification of the parasite burden under favorable conditions of high stocking density and litter moisture [4].
## Pathogenesis and Clinical Signs
The pathological effects of *E. maxima* are directly attributable to the destruction of intestinal epithelial cells during merogony and gametogony. The parasite preferentially invades the enterocytes of the jejunal villi, causing villous atrophy, crypt hyperplasia, and fusion of adjacent villi [5]. These morphological changes result in a marked reduction in the absorptive surface area of the midgut, leading to malabsorption of nutrients, particularly fats and fat-soluble vitamins.
Clinically, infected birds exhibit a range of signs that correlate with the magnitude of the infectious dose. In mild to moderate infections, birds may appear clinically normal but demonstrate reduced weight gain and poorer feed conversion ratios. In severe infections, birds develop diarrhea, which may be mucoid or watery, and exhibit ruffled feathers, depression, and huddling behavior [6]. Mortality is generally low in *E. maxima* infections compared to *E. necatrix* or *E. tenella*, but morbidity can be high, particularly in young broiler flocks.
The gross pathological lesions observed at necropsy are confined to the midgut. The jejunum and proximal ileum appear distended and edematous, with a thickened, friable wall. The serosal surface may exhibit petechial hemorrhages, and the mucosal surface is covered with a characteristic orange to pinkish mucoid exudate containing sloughed epithelial cells, fibrin, and oocysts [7]. In severe cases, the intestinal contents may be tinged with blood, although frank hemorrhage is less common than in cecal coccidiosis caused by *E. tenella*.
## Lesion Scoring System
The standardized lesion scoring system for *E. maxima* was developed to provide a reproducible, semi-quantitative method for assessing the severity of intestinal pathology in experimental and field settings. The system, originally described by Johnson and Reid, assigns a score from 0 (no lesions) to 4 (severe lesions) based on macroscopic examination of the midgut [8]. The scoring criteria are as follows:
**Score 0:** No gross lesions. The intestinal wall is of normal thickness, and the mucosal surface is intact without exudate or petechiae.
**Score 1:** Mild lesions. The intestinal wall is slightly thickened, and the mucosal surface may exhibit a few scattered petechiae. A small amount of thin, watery to mucoid exudate may be present. The intestinal contents are normal in consistency.
**Score 2:** Moderate lesions. The intestinal wall is moderately thickened and edematous. The mucosal surface shows numerous petechiae and small ecchymoses. A moderate amount of orange to pink mucoid exudate is present, and the intestinal contents may be watery.
**Score 3:** Severe lesions. The intestinal wall is markedly thickened and edematous, with a "sausage-like" appearance. The mucosal surface is covered with a thick, tenacious, orange to pink mucoid exudate that adheres to the epithelium. Petechiae and ecchymoses are confluent in some areas. The intestinal contents are fluid and may contain streaks of blood.
**Score 4:** Extremely severe lesions. The intestinal wall is severely thickened and hemorrhagic. The mucosal surface is covered with a thick, bloody exudate, and the lumen may contain frank blood clots. The intestinal wall may be friable and prone to rupture upon manipulation. Birds with score 4 lesions are typically moribund or dead.
This scoring system is widely used in anticoccidial efficacy trials, vaccine challenge studies, and epidemiological surveys. Lesion scoring is most reliable when performed by a single, trained observer to minimize inter-observer variability, and when birds are examined at the peak of lesion development, which occurs approximately 5 to 6 days post-infection for *E. maxima* [9].
## Differential Diagnosis
The clinical signs and gross lesions of *E. maxima* infection must be differentiated from other causes of enteritis in chickens. Key differential diagnoses include:
- **[Necrotic enteritis](/knowledge/bacteria/avian-bacteria/poultry-necrotic-enteritis-pathogenesis-control) (Clostridium perfringens type A):** Presents with a "Turkish towel" appearance of the intestinal mucosa, characterized by a thick, necrotic pseudomembrane. Lesions are often more diffuse and may involve the entire small intestine. Histopathology reveals coagulative necrosis and large Gram-positive rods [3].
- **Other Eimeria species:** *E. acervulina* causes lesions in the duodenum (upper small intestine) with characteristic white, transverse bands. *E. necatrix* produces severe hemorrhagic lesions in the midgut but also forms white, pinpoint foci in the ceca. *E. brunetti* affects the lower intestine and rectum, producing a thickened, corrugated mucosa [4].
- **Salmonellosis:** Caused by *Salmonella* spp., this condition produces focal necrotic lesions in the liver, spleen, and ceca, with or without enteritis. Bacterial culture and serotyping are required for definitive diagnosis [10].
- **[Avian influenza](/knowledge/bacteria/avian-bacteria/avian-influenza-cdc-global-surveillance) and Newcastle disease:** These viral infections can cause hemorrhagic enteritis but are typically accompanied by respiratory or neurological signs and systemic involvement [11].
## Immunity to Eimeria maxima
The immune response to *E. maxima* is complex and involves both innate and adaptive mechanisms. A hallmark of *E. maxima* infection is its ability to induce strong, species-specific protective immunity following a single infection. This immunogenicity is greater than that observed for *E. acervulina* or *E. tenella*, making *E. maxima* a critical component of live coccidiosis vaccines [12].
### Innate Immune Responses
The initial host response to *E. maxima* sporozoite invasion involves the activation of intestinal epithelial cells, which secrete chemokines and cytokines that recruit inflammatory cells to the site of infection. Macrophages and dendritic cells play a central role in antigen presentation and the initiation of adaptive immunity. Natural killer (NK) cells are also activated and contribute to early parasite control through the production of interferon-gamma (IFN-γ) [13].
### Adaptive Immune Responses
Protective immunity against *E. maxima* is primarily mediated by T lymphocytes, particularly CD4+ and CD8+ T cells. CD4+ T cells are essential for the induction of the immune response, while CD8+ cytotoxic T cells are the primary effector cells responsible for killing intracellular parasites [14]. The role of humoral immunity is less clear; although *E. maxima* induces a strong antibody response (IgA, IgM, and IgG), passive transfer of antibodies provides only partial protection, suggesting that cell-mediated immunity is the dominant protective mechanism [15].
The intestinal mucosa is the primary site of immune activation. Intraepithelial lymphocytes (IELs) and lamina propria lymphocytes (LPLs) proliferate in response to infection, and the production of IFN-γ by these cells is critical for controlling parasite replication. IFN-γ activates macrophages to produce nitric oxide and other reactive oxygen species that are toxic to intracellular parasites [16].
### Immune Evasion
Despite the strong immunogenicity of *E. maxima*, the parasite has evolved mechanisms to evade the host immune response. These include antigenic variation, particularly in the surface antigens (e.g., EmSAG proteins) expressed on sporozoites and merozoites, and the ability to modulate host cytokine responses to favor parasite survival [17]. The development of immunity is also dose-dependent; very low or very high doses of oocysts may result in incomplete protection, a phenomenon known as the "immune window" [18].
## Diagnostic Approaches
Definitive diagnosis of *E. maxima* infection relies on a combination of clinical history, gross pathology, histopathology, and parasitological examination.
### Fecal Flotation and Oocyst Morphology
Oocysts of *E. maxima* are the largest of the chicken *Eimeria* species, measuring approximately 20-30 µm by 16-20 µm. They are ellipsoidal to ovoid in shape and have a smooth, colorless wall. The oocyst wall lacks a micropyle, and an oocyst residuum is absent. Sporulation time at 25-30°C is approximately 24-30 hours [1]. Fecal flotation using saturated sodium chloride or Sheather's sugar solution is the standard method for oocyst detection and quantification. Oocyst counts are expressed as oocysts per gram (OPG) of feces.
### Histopathology
Histological examination of the midgut reveals the presence of developmental stages of the parasite within enterocytes. Schizonts, gametocytes, and oocysts can be identified in tissue sections stained with hematoxylin and eosin (H&E). The characteristic lesion of villous atrophy and crypt hyperplasia is readily apparent [5].
### Molecular Diagnostics
PCR-based assays targeting the internal transcribed spacer 1 (ITS-1) region of ribosomal DNA are available for species-specific identification of *E. maxima*. These assays are highly sensitive and can detect low-level infections that may be missed by microscopy. Quantitative PCR (qPCR) allows for the quantification of parasite DNA and can be used to monitor infection dynamics in experimental and field settings [19].
## Control and Prevention
Control of *E. maxima* in commercial poultry operations relies on a combination of management practices, anticoccidial drugs, and vaccination.
### Management Practices
Good biosecurity and litter management are essential for reducing environmental oocyst loads. Litter should be kept dry, as oocysts sporulate more rapidly in moist conditions. Adequate ventilation, proper stocking density, and all-in/all-out production systems help to break the parasite life cycle [20].
### Anticoccidial Drugs
Ionophore antibiotics (e.g., monensin, salinomycin, narasin) and chemical coccidiostats (e.g., diclazuril, toltrazuril) are widely used for the prevention and treatment of coccidiosis. However, resistance to both classes of drugs has been documented in *E. maxima* field isolates, necessitating rotation or shuttle programs to maintain efficacy [21].
### Vaccination
Live vaccines containing attenuated or non-attenuated strains of *E. maxima* are available and are administered via spray, drinking water, or gel beads. Vaccination induces protective immunity but requires careful management to ensure uniform vaccine intake and to avoid clinical disease from vaccine strains. The strong immunogenicity of *E. maxima* makes it a key component of multivalent coccidiosis vaccines [12].
## Conclusion
*Eimeria maxima* is a highly significant pathogen of chickens, causing midgut coccidiosis characterized by malabsorption, reduced growth performance, and characteristic gross lesions. The standardized lesion scoring system provides a valuable tool for assessing disease severity and evaluating control measures. The parasite's strong immunogenicity makes it a target for vaccination, but its ability to evade immune responses and develop drug resistance presents ongoing challenges for the poultry industry. Continued research into the molecular mechanisms of host-parasite interactions and the development of novel control strategies is essential for sustainable management of this economically important disease.
## References
[1] McDougald, L. R., & Fitz-Coy, S. H. (2013). Coccidiosis. In D. E. Swayne, J. R. Glisson, L. R. McDougald, L. K. Nolan, D. L. Suarez, & V. L. Nair (Eds.), *Diseases of Poultry* (13th ed., pp. 1148-1166). Wiley-Blackwell.
[2] Chapman, H. D. (2014). Milestones in [avian coccidiosis](/knowledge/parasites/avian-parasites/avian-coccidiosis-anticoccidial-medications-control-strategies-poultry) research: A review. *Poultry Science*, 93(3), 501-511.
[3] Williams, R. B. (2005). Intercurrent coccidiosis and [necrotic enteritis](/knowledge/bacteria/avian-bacteria/necrotic-enteritis-poultry) of chickens: Rational, integrated disease management by maintenance of gut integrity. *Avian Pathology*, 34(3), 159-180.
[4] Long, P. L., & Joyner, L. P. (1984). Problems in the identification of species of *Eimeria*. *Journal of Protozoology*, 31(4), 535-541.
[5] Fernando, M. A., & McCraw, B. M. (1973). Mucosal morphology and cellular renewal in the intestine of chickens following a single infection of *[Eimeria acervulina](/knowledge/parasites/avian-parasites/eimeria-acervulina-duodenal-coccidiosis-most-prevalent-chickens)*. *Journal of Parasitology*, 59(3), 493-501.
[6] Conway, D. P., & McKenzie, M. E. (2007). *[Poultry Coccidiosis](/knowledge/parasites/avian-parasites/coccidiosis-poultry-etiology-clinical-signs-therapeutic-management): Diagnostic and Testing Procedures* (3rd ed.). Blackwell Publishing.
[7] Johnson, J., & Reid, W. M. (1970). Anticoccidial drugs: Lesion scoring techniques in battery and floor-pen experiments with chickens. *Experimental Parasitology*, 28(1), 30-36.
[8] Reid, W. M., & Johnson, J. (1970). Pathogenicity of *[Eimeria acervulina](/knowledge/parasites/avian-parasites/eimeria-acervulina-duodenal-coccidiosis-most-prevalent-chickens)* in light and heavy infections. *Avian Diseases*, 14(1), 166-171.
[9] Chapman, H. D. (1999). The development of immunity to *Eimeria* species in broilers given anticoccidial drugs. *Avian Pathology*, 28(2), 155-162.
[10] Gast, R. K. (2013). *Salmonella* infections. In D. E. Swayne, J. R. Glisson, L. R. McDougald, L. K. Nolan, D. L. Suarez, & V. L. Nair (Eds.), *Diseases of Poultry* (13th ed., pp. 677-736). Wiley-Blackwell.
[11] Swayne, D. E., & Suarez, D. L. (2000). Highly pathogenic [avian influenza](/knowledge/bacteria/avian-bacteria/avian-influenza-cdc-guidelines-poultry-pandemic-preparedness). *Revue Scientifique et Technique (International Office of Epizootics)*, 19(2), 463-482.
[12] Williams, R. B. (2002). Anticoccidial vaccines for broiler chickens: Pathways to success. *Avian Pathology*, 31(4), 317-353.
[13] Lillehoj, H. S., & Trout, J. M. (1996). Avian gut-associated lymphoid tissues and intestinal immune responses to *Eimeria* parasites. *Clinical Microbiology Reviews*, 9(3), 349-360.
[14] Yun, C. H., Lillehoj, H. S., & Lillehoj, E. P. (2000). Intestinal immune responses to coccidiosis. *Developmental and Comparative Immunology*, 24(2-3), 303-324.
[15] Rose, M. E., & Hesketh, P. (1976). Immunity to coccidiosis: Stages of the life-cycle of *Eimeria maxima* which induce, and are affected by, the response of the host. *Parasitology*, 73(1), 25-37.
[16] Lillehoj, H. S., & Choi, K. D. (1998). Recombinant chicken interferon-gamma-mediated inhibition of *[Eimeria tenella](/knowledge/parasites/avian-parasites/eimeria-tenella-chickens-cecal-coccidiosis-anticoccidial-resistance)* development in vitro and reduction of oocyst production and body weight loss following *[Eimeria acervulina](/knowledge/parasites/avian-parasites/eimeria-acervulina-duodenal-coccidiosis-most-prevalent-chickens)* challenge infection. *Avian Diseases*, 42(2), 307-314.
[17] Tomley, F. M., & Shirley, M. W. (2000). *Eimeria* species: The genetics of antigenic diversity. *International Journal for Parasitology*, 30(4), 485-494.
[18] Rose, M. E., & Hesketh, P. (1982). Immunity to coccidiosis: T-lymphocyte or B-lymphocyte deficient animals. *Infection and Immunity*, 35(1), 135-140.
[19] Schnitzler, B. E., Thebo, P. L., Mattsson, J. G., Tomley, F. M., & Shirley, M. W. (1998). Development of a diagnostic PCR assay for the detection and discrimination of four pathogenic *Eimeria* species of the chicken. *Avian Pathology*, 27(5), 490-497.
[20] Williams, R. B. (1998). Epidemiological aspects of the use of live anticoccidial vaccines for chickens. *International Journal for Parasitology*, 28(7), 1089-1098.
[21] Chapman, H. D. (1997). Biochemical, genetic and applied aspects of drug resistance in *Eimeria* parasites of the fowl. *Avian Pathology*, 26(2), 221-244.
## Related Clinical & Scientific Guides
* [Tick-Borne Diseases in Dogs: Pathogens, Clinical Signs, Diagnosis, and Prevention](/knowledge/parasites/general/tick-borne-diseases-dogs)
* [Toxoplasmosis in Cats and the Risk of Brain Infection in Humans](/knowledge/parasites/general/toxoplasmosis-cats-brain-infection-humans)
* [Dog Heartworm and Tick-Borne Disease Prevention](/knowledge/parasites/general/dog-heartworm-and-tick-borne-disease-prevention)